{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T07:10:04Z","timestamp":1751008204904,"version":"3.41.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019211","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019211","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Astropharma"},{"DOI":"10.13039\/100031723","name":"Amgen GmbH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031723","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100022606","name":"Almirall","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019718","name":"Boehringer-Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000555","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000555","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024879","name":"Janssen-Cilag","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024879","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023331","name":"Leo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020604","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020604","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023517","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023517","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020975","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Little is known about treatment survival in patients with plaque psoriasis who have received phototherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>to analyse treatment survival in patients with plaque psoriasis who had received photother\u00adapy, irrespective of the number of sessions and type of phototherapy, and to identify factors that influence the risk of treatment discontinuation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from the Psoriasis Registry Austria and the phototherapy registry of the Centre of Phototherapy at the Department of Dermatology and Venereology, Medical University of Graz, were retrospectively analysed using Kaplan\u2013Meier curves (logrank test) and a Cox (proportional hazards) regression analysis, irrespective of the number of phototherapy sessions or type of phototherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The analysis revealed an overall treatment survival rate of 70% and 66% after 1 and 3 years, respectively, with a median treatment survival of 5.5 years. However, treatment survival rates have significantly decreased compared with the rates reported in the prebiologic era [hazard ratio (HR) 1.98, P &amp;lt; 0.001]. While female sex did not influence overall treatment survival (HR 0.87, P = 0.28), the risk of treatment discontinuation was significantly lower in women aged \u2265 60 years (HR 0.49, P = 0.009). Moreover, patients with arthritis had an increased risk of treatment discontinuation (HR 1.69, P = 0.003). The involvement of high-impact body areas (including scalp, nail, or inverse and\/or genital body areas) did not alter treatment survival; however, palmar and\/or plantar involvement increased the risk of treatment discontinuation (HR 1.48, P = 0.006), especially in men (HR 2.19, P &amp;lt; 0.001). No significant differences in the treatment survival of phototherapy in patients were observed regarding the duration of the psoriasis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Male patients with psoriasis with palmar and\/or plantar involvement have the highest risk of treatment discontinuation, whereas women aged \u2265 60 years at treatment start have the lowest risk. Therefore, early treatment escalation should be considered in men with palmar and\/or plantar involvement and treatment-resistance disease forms. However, the current treatment survival rates reported for patients with psoriasis treated with phototherapy (median survival 30 months) are similar to the treatment survival rates reported for patients receiving tumour necrosis factor inhibitors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/skinhd\/vzaf021","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T16:30:15Z","timestamp":1747413015000},"page":"214-222","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of treatment survival in patients with plaque psoriasis treated with phototherapy: registry analysis"],"prefix":"10.1093","volume":"5","author":[{"given":"Thomas","family":"Graier","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Graz , Graz ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Bordag","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Graz , Graz ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Hofer","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Graz , Graz ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Gruber-Wackernagel","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Graz , Graz ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz","family":"Legat","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Graz , Graz ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Widnig","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Graz , Graz ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Falkensteiner","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Graz , Graz ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Weger","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Graz , Graz ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Salmhofer","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Graz , Graz ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Wolf","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Graz , Graz ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"2025062702354192100_vzaf021-B1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"2025062702354192100_vzaf021-B2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/phpp.12088","article-title":"Phototherapy, psoriasis, and the age of biologics","volume":"30","author":"Richard","year":"2013","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2025062702354192100_vzaf021-B3","first-page":"1092","article-title":"German S3-Guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm \u2013 part 2: treatment monitoring and specific clinical or comorbid situations","volume":"19","author":"Nast","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025062702354192100_vzaf021-B4","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jaad.2017.11.036","article-title":"Drug survival of secukinumab in real-world plaque psoriasis patients: a 52-week, multicenter, retrospective study","volume":"78","author":"Georgakopoulos","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2025062702354192100_vzaf021-B5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjd.13343","article-title":"Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris","volume":"172","author":"Gniadecki","year":"2015","journal-title":"Br J Dermatol"},{"key":"2025062702354192100_vzaf021-B6","doi-asserted-by":"crossref","first-page":"15078","DOI":"10.1038\/s41598-022-18790-9","article-title":"Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)","volume":"12","author":"Graier","year":"2022","journal-title":"Sci Rep"},{"key":"2025062702354192100_vzaf021-B7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jdin.2020.10.012","article-title":"Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: a registry analysis","volume":"2","author":"Graier","year":"2021","journal-title":"JAAD Int"},{"key":"2025062702354192100_vzaf021-B8","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/ije\/dyy013","article-title":"Data maturity and follow-up in time-to-event analyses","volume":"47","author":"Gebski","year":"2018","journal-title":"Int J Epidemiol"},{"key":"2025062702354192100_vzaf021-B9","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1111\/jdv.17519","article-title":"The use of psoriasis biomarkers, including trajectory of clinical response, to predict clearance and remission duration to UVB phototherapy","volume":"35","author":"Watson","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025062702354192100_vzaf021-B10","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jdv.18846","article-title":"Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: week 52 results from the STEPIn study","volume":"37","author":"Iversen","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025062702354192100_vzaf021-B11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/1346-8138.12102","article-title":"Comparison of clinical effects of psoriasis treatment regimens among calcipotriol alone, narrowband ultraviolet B phototherapy alone, combination of calcipotriol and narrowband ultraviolet B phototherapy once a week, and combination of calcipotriol and narrowband ultraviolet B phototherapy more than twice a week","volume":"40","author":"Takahashi","year":"2013","journal-title":"J Dermatol"},{"key":"2025062702354192100_vzaf021-B12","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0190-9622(99)70008-3","article-title":"A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis","volume":"41","author":"Gordon","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"2025062702354192100_vzaf021-B13","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/bjd.19701","article-title":"Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis","volume":"184","author":"Graier","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025062702354192100_vzaf021-B14","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jdv.15324","article-title":"Gender and age significantly determine patient needs and treatment goals in psoriasis \u2013 a lesson for practice","volume":"33","author":"Maul","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025062702354192100_vzaf021-B15","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study","volume":"37","author":"Sch\u00e4kel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025062702354192100_vzaf021-B16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2133.2011.10616.x","article-title":"Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial","volume":"166","author":"Wolf","year":"2012","journal-title":"Br J Dermatol"},{"key":"2025062702354192100_vzaf021-B17","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1365-2133.2008.08926.x","article-title":"Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept","volume":"160","author":"Wolf","year":"2009","journal-title":"Br J Dermatol"},{"key":"2025062702354192100_vzaf021-B18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/bjd.12277","article-title":"Synergism between narrowband ultraviolet B phototherapy and etanercept for the treatment of plaque-type psoriasis","volume":"169","author":"Calzavara-Pinton","year":"2013","journal-title":"Br J Dermatol"},{"key":"2025062702354192100_vzaf021-B19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1600-0781.2011.00594.x","article-title":"311 nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients","volume":"27","author":"Wolf","year":"2011","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2025062702354192100_vzaf021-B20","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archderm.143.8.1016","article-title":"Narrowband UV-B photo\u00adtherapy, alefacept, and clearance of psoriasis","volume":"143","author":"Legat","year":"2007","journal-title":"Arch Dermatol"},{"key":"2025062702354192100_vzaf021-B21","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000491782","article-title":"Prevalence of phototherapy in the age of biologics","volume":"234","author":"Calzavara-Pinton","year":"2018","journal-title":"Dermatology"},{"key":"2025062702354192100_vzaf021-B22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","article-title":"Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis","volume":"81","author":"Gisondi","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025062702354192100_vzaf021-B23","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1002\/ski2.263","article-title":"No impact of disease duration on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis: post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies","volume":"3","author":"Griss","year":"2023","journal-title":"Skin Health Dis"},{"key":"2025062702354192100_vzaf021-B24","first-page":"1513","article-title":"Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004\u20132022","volume":"21","author":"Graier","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025062702354192100_vzaf021-B25","first-page":"CD009481","article-title":"Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis","volume":"2013","author":"Chen","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025062702354192100_vzaf021-B26","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1002\/ski2.355","article-title":"Psoriasis and its impact on close relatives and partners of patients \u2013 a cross-sectional questionnaire study","volume":"4","author":"Grossschaedl","year":"2024","journal-title":"Skin Health Dis"},{"author":"Statistik Austria","key":"2025062702354192100_vzaf021-B27"},{"key":"2025062702354192100_vzaf021-B28","doi-asserted-by":"crossref","first-page":"e14276","DOI":"10.1111\/dth.14276","article-title":"Trends in psoriasis treatment 2005 to 2018: declining phototherapy utilization and concomitant increased use of biologics","volume":"33","author":"Do","year":"2020","journal-title":"Dermatol Ther"},{"key":"2025062702354192100_vzaf021-B29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1067\/mjd.2002.120451","article-title":"Phototherapy utilization for psoriasis is declining in the United States","volume":"46","author":"Housman","year":"2002","journal-title":"J Am Acad Dermatol"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/5\/3\/214\/63212167\/vzaf021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/5\/3\/214\/63212167\/vzaf021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T06:35:56Z","timestamp":1751006156000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/5\/3\/214\/8133884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,5,16]]},"published-print":{"date-parts":[[2025,6,27]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzaf021","relation":{},"ISSN":["2690-442X"],"issn-type":[{"type":"electronic","value":"2690-442X"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,5,16]]}}}